The Neat-HER virtual registry: Updated results on HER2+breast cancer patients receiving neratinib as extended adjuvant therapy.

被引：0
|
作者：
Vidal, Gregory A.
Tripathy, Debu
Hill, Nina
Lalla, Deepa
Hanson, Gillian
Drozd, Daniel R.
Xu, Feng
Rugo, Hope S.
机构：
[1] West Canc Ctr & Res Inst, Memphis, TN USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Univ Calif San Francisco, Puma Biotechnol Inc, San Francisco, CA 94143 USA
[4] Puma Biotechnol Inc, Los Angeles, CA USA
[5] PicnicHealth, San Francisco, CA USA
[6] Univ Calif San Francisco, Comprehens Canc Ctr, San Francisco, CA 94143 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e13565
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13565
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Adjuvant therapeutic approaches of HER2-positive breast cancer with a focus on neratinib maleate
    Kotecki, N.
    Gombos, A.
    Awada, A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (06) : 447 - 454
  • [42] Adjuvant Therapy for HER2-Positive Breast Cancer
    Slomski, Anita
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (12): : 1134 - 1134
  • [43] Adjuvant therapy in breast cancer HER2 positive
    Olivito, V.
    De Simone, R.
    La Gattuta, G.
    Lucia, M.
    Dima, G.
    Talarico, R.
    Filippelli, G.
    ANNALS OF ONCOLOGY, 2006, 17 : VII146 - VII146
  • [44] Perception, Practice and Toxicity of Adjuvant Treatment of HER2+Breast Cancer in Wisconsin.
    Rocque, G. B.
    Onitilo, A. A.
    Engel, J. M.
    Pettke, E. N.
    Boshoven, A. M.
    Zhang, S.
    Kim, K. M.
    Rishi, S.
    Waack, B.
    Wisinski, K. B.
    Tevaarwerk, A. J.
    Burkard, M. E.
    CANCER RESEARCH, 2011, 71
  • [45] Neratinib after trastuzumab in patients with HER2-positive breast cancer
    Hasegawa, Takahiro
    Uno, Hajime
    Wei, Lee-Jen
    LANCET ONCOLOGY, 2016, 17 (05): : E176 - E176
  • [46] Neratinib (HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor: phase 2 results in patients with advanced HER2+breast cancer
    Burstein, H. J.
    Sun, Y.
    Tan, A. R.
    Dirix, L.
    Vermette, J. J.
    Powell, C.
    Zacharchuk, C.
    Badwe, R. A.
    CANCER RESEARCH, 2009, 69 (02) : 72S - 73S
  • [47] A phase III trial of adjuvant neratinib (NER) after trastuzumab (TRAS) in women with early-stage HER2+breast cancer (BC).
    Goss, P. E.
    Barrios, C. H.
    Chan, A.
    Chia, S. K. L.
    Delaloge, S.
    Ejlertsen, B.
    Ingle, J. N.
    Moy, B.
    Iwata, H.
    Holmes, F. A.
    Mansi, J.
    Von Minckwitz, G.
    Han, L.
    Thiele, A.
    Agrapart, V.
    Freyman, A.
    Truscello, J.
    Berkenblit, A.
    Finkelstein, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [48] Safety and efficacy of neratinib in patients with HER 2 breast cancer: a systematic review
    Christianto, P.
    Kurniawan, A.
    Suhardi, R.
    Atmaja, W. S.
    Chan, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S1393 - S1393
  • [49] Pruritus related to trastuzumab and pertuzumab in HER2+breast cancer patients
    Gu, Stephanie
    Dusza, Stephen
    Quigley, Elizabeth
    Haliasos, Helen
    Markova, Alina
    Marchetti, Michael
    Moy, Andrea P.
    Dang, Chau
    Modi, Shanu
    Lake, Diana
    Noor, Sarah
    Lacouture, Mario E.
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 203 (02) : 271 - 280
  • [50] Response of HER2+breast cancer patients to allogeneic cell immunotherapy
    Har-Noy, Michael
    Lausoontornsiri, Wirote
    Or, Reuven
    Katsanis, Emmanual
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345